Skip to content

Publications​​

Click on the button to submit any research proposal and send to to the respective committee or the board

Go to submission Form
  1. Hughes, M, Heal, C, Henes, J, Balbir-Gurman, A, Distler, JHW, Airò, P et al.. Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford). 2022;61 (3):1141-1147. doi: 10.1093/rheumatology/keab510. PubMed PMID:34146098 .
  2. Iudici, M, Jarlborg, M, Lauper, K, Müller-Ladner, U, Smith, V, Allanore, Y et al.. Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology (Oxford). 2022;61 (2):743-755. doi: 10.1093/rheumatology/keab437. PubMed PMID:33989387 .
  3. Gigante, A, Hoffmann-Vold, AM, Alunni Fegatelli, D, Gabrielli, A, Leodori, G, Coleiro, B et al.. Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. Rheumatology (Oxford). 2021;61 (1):213-222. doi: 10.1093/rheumatology/keab302. PubMed PMID:33769468 .
  4. Lazzaroni, MG, Marasco, E, Campochiaro, C, DeVries-Bouwstra, J, Gonzalez-Perez, MI, Rojas-Serrano, J et al.. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology (Oxford). 2021;60 (11):5028-5041. doi: 10.1093/rheumatology/keab152. PubMed PMID:33580257 .
  5. Allanore, Y, Bozzi, S, Terlinden, A, Huscher, D, Amand, C, Soubrane, C et al.. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Res Ther. 2020;22 (1):257. doi: 10.1186/s13075-020-02329-2. PubMed PMID:33115544 PubMed Central PMC7592571.
  6. Benvenuti, F, Zanatta, E, Avouac, J, Müller-Ladner, U, Cozzi, F, Hoffmann-Vold, AM et al.. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Rev Clin Immunol. 2020;16 (11):1065-1074. doi: 10.1080/1744666X.2021.1836962. PubMed PMID:33076716 .
  7. Hoffmann-Vold, AM, Allanore, Y, Alves, M, Brunborg, C, Airó, P, Ananieva, LP et al.. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80 (2):219-227. doi: 10.1136/annrheumdis-2020-217455. PubMed PMID:32988845 PubMed Central PMC7815627.
  8. Bruni, C, Tashkin, DP, Steen, V, Allanore, Y, Distler, O, Grotts, J et al.. Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. Clin Exp Rheumatol. ;38 Suppl 125 (3):161-168. . PubMed PMID:32865169 .
  9. Hughes, M, Heal, C, Siegert, E, Hachulla, E, Airó, P, Riccardi, A et al.. Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2020;79 (8):1123-1125. doi: 10.1136/annrheumdis-2020-217035. PubMed PMID:32213494 .
  10. Bütikofer, L, Varisco, PA, Distler, O, Kowal-Bielecka, O, Allanore, Y, Riemekasten, G et al.. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis Res Ther. 2020;22 (1):59. doi: 10.1186/s13075-020-2141-2. PubMed PMID:32209135 PubMed Central PMC7093969.
  11. Castellví, I, Elhai, M, Bruni, C, Airò, P, Jordan, S, Beretta, L et al.. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. Semin Arthritis Rheum. 2020;50 (6):1489-1493. doi: 10.1016/j.semarthrit.2019.12.004. PubMed PMID:32165035 .
  12. Frantz, C, Huscher, D, Avouac, J, Hachulla, E, Balbir-Gurman, A, Riemekasten, G et al.. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev. 2020;19 (2):102452. doi: 10.1016/j.autrev.2019.102452. PubMed PMID:31838157 .
  13. Mihai, C, Distler, O, Gheorghiu, AM, Constantin, PI, Dobrota, R, Jordan, S et al.. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology (Oxford). 2020;59 (8):2016-2023. doi: 10.1093/rheumatology/kez558. PubMed PMID:31790136 .
  14. Jaeger, VK, Tikly, M, Xu, D, Siegert, E, Hachulla, E, Airò, P et al.. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology (Oxford). 2020;59 (7):1684-1694. doi: 10.1093/rheumatology/kez486. PubMed PMID:31680161 .
  15. Radic, M, Becker, MO, Distler, O, Huscher, D, Siegert, E, Riemekasten, G et al.. Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. Clin Exp Rheumatol. ;37 Suppl 119 (4):154-155. . PubMed PMID:31573474 .
  16. Fasano, S, Riccardi, A, Messiniti, V, Caramaschi, P, Rosato, E, Maurer, B et al.. Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Ann Rheum Dis. 2019;78 (12):1681-1685. doi: 10.1136/annrheumdis-2019-215787. PubMed PMID:31422354 .
  17. Becker, M, Graf, N, Sauter, R, Allanore, Y, Curram, J, Denton, CP et al.. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis. 2019;78 (9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. PubMed PMID:31227488 PubMed Central PMC6788922.
  18. Blagojevic, J, Abignano, G, Avouac, J, Cometi, L, Frerix, M, Bellando-Randone, S et al.. Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. Clin Rheumatol. 2020;39 (1):27-36. doi: 10.1007/s10067-019-04564-8. PubMed PMID:31111363 .
  19. Hoffmann-Vold, AM, Distler, O, Murray, B, Kowal-Bielecka, O, Khanna, D, Allanore, Y et al.. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open. 2019;5 (1):e000826. doi: 10.1136/rmdopen-2018-000826. PubMed PMID:30997150 PubMed Central PMC6446182.
  20. Sobanski, V, Giovannelli, J, Allanore, Y, Riemekasten, G, Airò, P, Vettori, S et al.. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis Rheumatol. 2019;71 (9):1553-1570. doi: 10.1002/art.40906. PubMed PMID:30969034 PubMed Central PMC6771590.
  21. Elhai, M, Boubaya, M, Distler, O, Smith, V, Matucci-Cerinic, M, Alegre Sancho, JJ et al.. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78 (7):979-987. doi: 10.1136/annrheumdis-2018-214816. PubMed PMID:30967395 .
  22. Wu, W, Jordan, S, Graf, N, de Oliveira Pena, J, Curram, J, Allanore, Y et al.. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019;78 (5):648-656. doi: 10.1136/annrheumdis-2018-213455. PubMed PMID:30852552 PubMed Central PMC6517861.
  23. Blagojevic, J, Bellando-Randone, S, Abignano, G, Avouac, J, Cometi, L, Czirják, L et al.. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey. Arthritis Res Ther. 2019;21 (1):35. doi: 10.1186/s13075-019-1822-1. PubMed PMID:30678703 PubMed Central PMC6346551.
  24. Carreira, PE, Carmona, L, Joven, BE, Loza, E, Andreu, JL, Riemekasten, G et al.. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clin Exp Rheumatol. ;36 Suppl 113 (4):68-75. . PubMed PMID:30277860 .
  25. Carreira, PE, Carmona, L, Joven, BE, Loza, E, Andréu, JL, Riemekasten, G et al.. Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database. Scand J Rheumatol. 2019;48 (1):42-51. doi: 10.1080/03009742.2018.1459830. PubMed PMID:30039730 .
  26. Jaeger, VK, Valentini, G, Hachulla, E, Cozzi, F, Distler, O, Airó, P et al.. Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis Rheumatol. 2018;70 (11):1829-1834. doi: 10.1002/art.40557. PubMed PMID:29781588 .
  27. Adler, S, Huscher, D, Siegert, E, Allanore, Y, Czirják, L, DelGaldo, F et al.. Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20 (1):17. doi: 10.1186/s13075-018-1517-z. PubMed PMID:29382380 PubMed Central PMC5791165.
  28. Elhai, M, Meune, C, Boubaya, M, Avouac, J, Hachulla, E, Balbir-Gurman, A et al.. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76 (11):1897-1905. doi: 10.1136/annrheumdis-2017-211448. PubMed PMID:28835464 .
  29. Carreira, PE, Carmona, L, Joven, BE, Loza, E, Andreu, JL, Riemekasten, G et al.. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clin Exp Rheumatol. ;35 Suppl 106 (4):114-121. . PubMed PMID:28664832 .
  30. Jaeger, VK, Distler, O, Maurer, B, Czirják, L, Lóránd, V, Valentini, G et al.. Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology (Oxford). 2018;57 (3):441-450. doi: 10.1093/rheumatology/kex182. PubMed PMID:28499034 .
  31. Kowal-Bielecka, O, Chwiesko-Minarowska, S, Bernatowicz, PL, Allanore, Y, Radstake, T, Matucci-Cerinic, M et al.. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology (Oxford). 2017;56 (5):844-852. doi: 10.1093/rheumatology/kew499. PubMed PMID:28160477 .
  32. Lazzaroni, MG, Cavazzana, I, Colombo, E, Dobrota, R, Hernandez, J, Hesselstrand, R et al.. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. J Rheumatol. 2017;44 (5):639-647. doi: 10.3899/jrheum.160817. PubMed PMID:28089973 .
  33. Kowal-Bielecka, O, Fransen, J, Avouac, J, Becker, M, Kulak, A, Allanore, Y et al.. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76 (8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. PubMed PMID:27941129 .
  34. Jaeger, VK, Wirz, EG, Allanore, Y, Rossbach, P, Riemekasten, G, Hachulla, E et al.. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS One. 2016;11 (10):e0163894. doi: 10.1371/journal.pone.0163894. PubMed PMID:27706206 PubMed Central PMC5051961.
  35. Valentini, G, Iudici, M, Walker, UA, Jaeger, VK, Baron, M, Carreira, P et al.. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76 (1):270-276. doi: 10.1136/annrheumdis-2016-209768. PubMed PMID:27621285 .
  36. Dobrota, R, Maurer, B, Graf, N, Jordan, S, Mihai, C, Kowal-Bielecka, O et al.. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis. 2016;75 (10):1743-8. doi: 10.1136/annrheumdis-2015-208024. PubMed PMID:27016052 PubMed Central PMC5036205.
  37. Sandmeier, B, Jäger, VK, Nagy, G, Carreira, PE, Tzankov, A, Widuchowska, M et al.. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clin Exp Rheumatol. ;33 (4 Suppl 91):S75-9. . PubMed PMID:26339891 .
  38. Ingegnoli, F, Boracchi, P, Gualtierotti, R, Smith, V, Cutolo, M, Foeldvari, I et al.. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvasc Res. 2015;102 :19-24. doi: 10.1016/j.mvr.2015.07.007. PubMed PMID:26254260 .
  39. Brand, M, Hollaender, R, Rosenberg, D, Scott, M, Hunsche, E, Tyndall, A et al.. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol. ;33 (4 Suppl 91):S47-54. . PubMed PMID:26243652 .
  40. Wirz, EG, Jaeger, VK, Allanore, Y, Riemekasten, G, Hachulla, E, Distler, O et al.. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75 (7):1285-92. doi: 10.1136/annrheumdis-2015-207271. PubMed PMID:26232495 .
  41. Mihai, C, Landewé, R, van der Heijde, D, Walker, UA, Constantin, PI, Gherghe, AM et al.. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2016;75 (4):681-6. doi: 10.1136/annrheumdis-2014-205897. PubMed PMID:25688073 .
  42. Hachulla, E, Clerson, P, Airò, P, Cuomo, G, Allanore, Y, Caramaschi, P et al.. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology (Oxford). 2015;54 (7):1262-9. doi: 10.1093/rheumatology/keu450. PubMed PMID:25596413 PubMed Central PMC4473765.
  43. Elhai, M, Avouac, J, Walker, UA, Matucci-Cerinic, M, Riemekasten, G, Airò, P et al.. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75 (1):163-9. doi: 10.1136/annrheumdis-2014-206386. PubMed PMID:25342760 .
  44. Avouac, J, Walker, UA, Hachulla, E, Riemekasten, G, Cuomo, G, Carreira, PE et al.. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75 (1):103-9. doi: 10.1136/annrheumdis-2014-205295. PubMed PMID:25165035 .
  45. Maurer, B, Graf, N, Michel, BA, Müller-Ladner, U, Czirják, L, Denton, CP et al.. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015;74 (6):1124-31. doi: 10.1136/annrheumdis-2014-205226. PubMed PMID:24981642 .
  46. Jordan, S, Distler, JH, Maurer, B, Huscher, D, van Laar, JM, Allanore, Y et al.. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74 (6):1188-94. doi: 10.1136/annrheumdis-2013-204522. PubMed PMID:24442885 .
  47. Keck, AD, Foocharoen, C, Rosato, E, Smith, V, Allanore, Y, Distler, O et al.. Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. Rheumatology (Oxford). 2014;53 (4):639-43. doi: 10.1093/rheumatology/ket392. PubMed PMID:24310296 .
  48. Ghrénassia, E, Avouac, J, Khanna, D, Derk, CT, Distler, O, Suliman, YA et al.. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol. 2014;41 (1):99-105. doi: 10.3899/jrheum.130386. PubMed PMID:24293584 .
  49. Müller-Ladner, U, Tyndall, A, Czirjak, L, Denton, C, Matucci-Cerinic, M, EUSTAR centres et al.. Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved?. Ann Rheum Dis. 2014;73 (2):324-7. doi: 10.1136/annrheumdis-2013-203997. PubMed PMID:24121165 .
  50. Minier, T, Guiducci, S, Bellando-Randone, S, Bruni, C, Lepri, G, Czirják, L et al.. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73 (12):2087-93. doi: 10.1136/annrheumdis-2013-203716. PubMed PMID:23940211 .
  51. Ingegnoli, F, Ardoino, I, Boracchi, P, Cutolo, M, EUSTAR co-authors. Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. Microvasc Res. 2013;89 :122-8. doi: 10.1016/j.mvr.2013.06.003. PubMed PMID:23792167 .
  52. Elhai, M, Meunier, M, Matucci-Cerinic, M, Maurer, B, Riemekasten, G, Leturcq, T et al.. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72 (7):1217-20. doi: 10.1136/annrheumdis-2012-202657. PubMed PMID:23253926 .
  53. Schneeberger, D, Tyndall, A, Kay, J, Søndergaard, KH, Carreira, PE, Morgiel, E et al.. Systemic sclerosis without antinuclear antibodies or Raynaud’s phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013;52 (3):560-7. doi: 10.1093/rheumatology/kes315. PubMed PMID:23221323 .
  54. Heijnen, IA, Foocharoen, C, Bannert, B, Carreira, PE, Caporali, R, Smith, V et al.. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol. ;31 (2 Suppl 76):96-102. . PubMed PMID:23101460 .
  55. Saketkoo, LA, Escorpizo, R, Keen, KJ, Fligelstone, K, Distler, O, EUSTAR et al.. International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. Rheumatology (Oxford). 2012;51 (12):2170-6. doi: 10.1093/rheumatology/kes185. PubMed PMID:22919048 .
  56. Koumakis, E, Wipff, J, Dieudé, P, Ruiz, B, Bouaziz, M, Revillod, L et al.. TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Ann Rheum Dis. 2012;71 (11):1900-3. doi: 10.1136/annrheumdis-2012-201755. PubMed PMID:22896741 .
  57. Foeldvari, I, Tyndall, A, Zulian, F, Müller-Ladner, U, Czirjak, L, Denton, C et al.. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012;51 (10):1832-7. doi: 10.1093/rheumatology/kes144. PubMed PMID:22728264 .
  58. Meier, FM, Frommer, KW, Dinser, R, Walker, UA, Czirjak, L, Denton, CP et al.. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71 (8):1355-60. doi: 10.1136/annrheumdis-2011-200742. PubMed PMID:22615460 .
  59. Foocharoen, C, Distler, O, Becker, M, Müller-Ladner, U, von Mühlen, C, Leuchten, N et al.. Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol. 2012;41 (3):243-6. doi: 10.3109/03009742.2011.641583. PubMed PMID:22309107 .
  60. Distler, JH, Jordan, S, Airo, P, Alegre-Sancho, JJ, Allanore, Y, Balbir Gurman, A et al.. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol. ;29 (2 Suppl 65):S40-5. . PubMed PMID:21586217 .
  61. Fransen, J, Popa-Diaconu, D, Hesselstrand, R, Carreira, P, Valentini, G, Beretta, L et al.. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70 (10):1788-92. doi: 10.1136/ard.2010.144360. PubMed PMID:21784727 .
  62. Wipff, J, Coriat, R, Masciocchi, M, Caramaschi, P, Derk, CT, Hachulla, E et al.. Outcomes of Barrett’s oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology (Oxford). 2011;50 (8):1440-4. doi: 10.1093/rheumatology/ker110. PubMed PMID:21415021 .
  63. Beyer, C, Distler, JH, Allanore, Y, Aringer, M, Avouac, J, Czirják, L et al.. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis. 2011;70 (7):1178-82. doi: 10.1136/ard.2010.142489. PubMed PMID:21285118 .
  64. Avouac, J, Fransen, J, Walker, UA, Riccieri, V, Smith, V, Muller, C et al.. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70 (3):476-81. doi: 10.1136/ard.2010.136929. PubMed PMID:21081523 .
  65. Hügle, T, Schuetz, P, Daikeler, T, Tyndall, A, Matucci-Cerinic, M, Walker, UA et al.. Late-onset systemic sclerosis–a systematic survey of the EULAR scleroderma trials and research group database. Rheumatology (Oxford). 2011;50 (1):161-5. doi: 10.1093/rheumatology/keq321. PubMed PMID:20884657 .
  66. Tyndall, AJ, Bannert, B, Vonk, M, Airò, P, Cozzi, F, Carreira, PE et al.. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69 (10):1809-15. doi: 10.1136/ard.2009.114264. PubMed PMID:20551155 .
  67. Alizadeh, BZ, Broen, J, Rueda, B, Hesselstrand, R, Wuttge, D, Simeon, C et al.. Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European Study (EUSTAR). J Rheumatol. 2010;37 (8):1673-9. doi: 10.3899/jrheum.091259. PubMed PMID:20551103 .
  68. Avouac, J, Walker, U, Tyndall, A, Kahan, A, Matucci-Cerinic, M, Allanore, Y et al.. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010;37 (7):1488-501. doi: 10.3899/jrheum.091165. PubMed PMID:20551097 .
  69. Matucci-Cerinic, M, Allanore, Y, Czirják, L, Tyndall, A, Müller-Ladner, U, Denton, C et al.. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68 (9):1377-80. doi: 10.1136/ard.2008.106302. PubMed PMID:19674983 .
  70. Allanore, Y, Meune, C, Vonk, MC, Airo, P, Hachulla, E, Caramaschi, P et al.. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010;69 (1):218-21. doi: 10.1136/ard.2008.103382. PubMed PMID:19279015 .
  71. Kowal-Bielecka, O, Landewé, R, Avouac, J, Chwiesko, S, Miniati, I, Czirjak, L et al.. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68 (5):620-8. doi: 10.1136/ard.2008.096677. PubMed PMID:19147617 .
  72. Avouac, J, Kowal-Bielecka, O, Landewe, R, Chwiesko, S, Miniati, I, Czirjak, L et al.. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2009;68 (5):629-34. doi: 10.1136/ard.2008.095299. PubMed PMID:18957486 .
  73. Tyndall, A, Ladner, UM, Matucci-Cerinic, M. The EULAR Scleroderma Trials and Research Group (EUSTAR): an international framework for accelerating scleroderma research. Curr Opin Rheumatol. 2008;20 (6):703-6. doi: 10.1097/BOR.0b013e328311f841. PubMed PMID:18946332 .
  74. Distler, JH, Allanore, Y, Avouac, J, Giacomelli, R, Guiducci, S, Moritz, F et al.. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009;68 (2):163-8. doi: 10.1136/ard.2008.091918. PubMed PMID:18653485 .
  75. Walker, UA, Tyndall, A, Czirják, L, Denton, CP, Farge-Bancel, D, Kowal-Bielecka, O et al.. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis. 2009;68 (6):856-62. doi: 10.1136/ard.2008.091348. PubMed PMID:18625615 .
  76. Rozman, B, Cucnik, S, Sodin-Semrl, S, Czirják, L, Varjú, C, Distler, O et al.. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis. 2008;67 (9):1282-6. doi: 10.1136/ard.2007.073981. PubMed PMID:18063672 .
  77. Walker, UA, Tyndall, A, Czirják, L, Denton, C, Farge-Bancel, D, Kowal-Bielecka, O et al.. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66 (6):754-63. doi: 10.1136/ard.2006.062901. PubMed PMID:17234652 PubMed Central PMC1954657.
  78. Czirják, L, Nagy, Z, Aringer, M, Riemekasten, G, Matucci-Cerinic, M, Furst, DE et al.. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis. 2007;66 (7):966-9. doi: 10.1136/ard.2006.066530. PubMed PMID:17234649 PubMed Central PMC1955103.
  79. Allanore, Y, Borderie, D, Airo, P, Guiducci, S, Czirják, L, Nasonov, EL et al.. Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis. 2007;66 (2):257-9. doi: 10.1136/ard.2006.054346. PubMed PMID:16740682 PubMed Central PMC1798516.
  80. Tyndall, A, Mueller-Ladner, U, Matucci-Cerinic, M. Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann Rheum Dis. 2005;64 (7):1107. doi: 10.1136/ard.2005.036038. PubMed PMID:15958775 PubMed Central PMC1755555.

  81. Lescoat A, Huang S, Carreira PE, Siegert E, de Vries-Bouwstra J, Distler JHW, Smith V, Del Galdo F, Anic B, et al.Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database. JAMA Dermatol. 2023 Jun 28:e231729. doi: 10.1001/jamadermatol.2023.1729. Online ahead of print. PubMed PMID: 37378994

  82. Campochiaro C, Hoffmann-Vold AM, Avouac J, Henes J, de Vries-Bouwstra J, Smith V, Siegert E, Airò P, et al.Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis. Rheumatology (Oxford). 2023 Jul 5;62(7):2483-2491. doi: 10.1093/rheumatology/keac660. PubMedPMID: 36413079

  83. Iudici M, Mongin D, Siegert E, Carreira PE, Distler J, Henes J, Zanatta E, Hachulla E, De Luca G, de Souza Müller C, Santiago T, et al.Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. Rheumatology (Oxford). 2023;62(4):1559-1567. doi: 10.1093/rheumatology/keac533. PubMedPMID: 36099040

  84. Lescoat A, Huscher D, Schoof N, Airò P, de Vries-Bouwstra J, Riemekasten G, Hachulla E, et al.Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region.Rheumatology (Oxford). 2023;62(6):2178-2188. doi: 10.1093/rheumatology/keac576. PubMed PMID: 36222557

  85. Garaiman A, Steigmiller K, Gebhard C, Mihai C, Dobrota R, Bruni C, Matucci-Cerinic M, et al. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology (Oxford). 2023;62(SI):SI91-SI100. doi: 10.1093/rheumatology/keac405. PubMedPMID: 35904554

  86. Colalillo A, Hoffmann-Vold AM, Pellicano C, Romaniello A, Gabrielli A, Hachulla E, Smith V et al.The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. Autoimmun Rev. 2023;22(4):103290. doi: 10.1016/j.autrev.2023.103290. PubMedPMID: 36746368

  87. Hughes M, Huang S, Alegre-Sancho JJ, Carreira PE, Engelhart M, Hachulla E, et al.Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford). 2023;62(SI):SI54-SI63. doi: 10.1093/rheumatology/keac363. PubMedPMID: 35731139.

  88. Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C, Cacciapaglia F, et al.Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort.RMD Open. 2022;8(2):e002477. doi: 10.1136/rmdopen-2022-002477. PubMedPMID: 36328401

  89. Bruni C, Chung L, Hoffmann-Vold AM, Assassi S, Gabrielli A, Khanna D, Bernstein EJ, Distler O; et al.High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey.Clin Exp Rheumatol. 2022;40(10):1951-1955. doi: 10.55563/clinexprheumatol/7ry6zz. PubMed PMID: 35819810

  90. Zanatta E, Huscher D, Ortolan A, Avouac J, Airò P, Balbir-Gurman A, et al.Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology (Oxford). 2022;61(12):4786-4796. doi: 10.1093/rheumatology/keac188. PubMedPMID: 35348643

  91. Campochiaro C, Lazzaroni MG, Bruni C, Zanatta E, De Luca G, Matucci-Cerinic M. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720X221116408. doi: 10.1177/1759720X221116408. eCollection 2022. PubMedPMID: 36051631

Twitter Youtube Linkedin

© 2022 European Scleroderma Trials and Research Group (EUSTAR)